Role of Prohepcidin in Uremic Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Haseki Training and Research Hospital
ClinicalTrials.gov Identifier:
NCT01735773
First received: November 26, 2012
Last updated: November 27, 2012
Last verified: November 2012
  Purpose

The investigators aimed to study the effect of prohepcidin levels on hematologic parameters and inflammatory markers in non-diabetic uremic patients. The investigators selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also. Each group has been planned to be formed of about 25 patients. Diabetic patients were excluded. Prohepcidin, hsCRP, IL-6, fibrinogen have been planned to be studied besides other routine biochemical analysis including hematological ones.


Condition
Inflammation
Chronic Kidney Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Relationship of Prohepcidin Levels With Anemia and Inflammatory Markers in Non-diabetic Uremic Patients: A Controlled Study

Resource links provided by NLM:


Further study details as provided by Haseki Training and Research Hospital:

Primary Outcome Measures:
  • prohepcidin level [ Time Frame: Six months ] [ Designated as safety issue: No ]
    Prohepcidin levels will be compared with other inflammatory markers.


Secondary Outcome Measures:
  • Anemia and inflammatory markers [ Time Frame: Six months ] [ Designated as safety issue: No ]
    Correlations of prohepcidin levels with anemia and inflamatory markers


Enrollment: 25
Study Start Date: January 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Hemodialysis group
Patients on chronic hemodialysis program
Peritoneal dialysis group
Patients on chronic peritoneal dialysis program
Pre-dialysis group
Patients with chronic kidney disease stage-4
Control group
Healthy volunteers

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

We selected three groups of patients: Hemodialysis group, peritoneal dialysis group and the group with stage 4 chronic kidney disease. A control group was formed from healthy volunteers also.

Criteria

Inclusion Criteria:

  • hemodialysis and peritoneal dialysis patients who had been on dialysis therapy for more than 3 months,
  • age between 18-80 years,
  • patients with creatinine clearance between 15-30 ml/min.

Exclusion Criteria:

  • age less than 18 or more than 80,
  • diabetic patients,
  • current active infectious or inflammatory disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01735773

Locations
Turkey
Haseki Training and Research Hospital
Istanbul, Turkey, 34390
Sponsors and Collaborators
Haseki Training and Research Hospital
  More Information

No publications provided

Responsible Party: Haseki Training and Research Hospital
ClinicalTrials.gov Identifier: NCT01735773     History of Changes
Other Study ID Numbers: HEPCIDIN-HASEKI
Study First Received: November 26, 2012
Last Updated: November 27, 2012
Health Authority: Turkey: Ministry of Health

Keywords provided by Haseki Training and Research Hospital:
hemodialysis
inflammation
iron
peritoneal dialysis
prohepcidin
uremia

Additional relevant MeSH terms:
Inflammation
Kidney Diseases
Renal Insufficiency, Chronic
Pathologic Processes
Urologic Diseases
Renal Insufficiency
Hepcidins
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 01, 2014